Research chemicals

GHB (gamma-hydroxybutyrate) is a CNS depressant that occurs naturally in the body and is used medically as sodium oxybate for narcolepsy. Recreationally it produces euphoria, sedation and disinhibition, but it has an unusually narrow dose-response: the gap between a recreational dose and one causing unconsciousness, coma or respiratory arrest is small, and it is measured in millilitres or grams that are easy to misjudge. Combining GHB with alcohol sharply raises the risk of coma and death.

Phencyclidine (PCP, 'angel dust') is the prototype arylcyclohexylamine dissociative, developed in the 1950s as a surgical anaesthetic before withdrawal due to severe emergence reactions. It is an NMDA receptor antagonist producing dissociation, analgesia and, at higher doses, marked agitation, psychosis and anaesthesia. Among this class it has one of the larger human data sets, drawn mostly from clinical anaesthesia trials and decades of emergency-department case reports.

GBL (gamma-butyrolactone) is an industrial solvent and a prodrug of GHB: once ingested it is rapidly converted to GHB by the body. It shares GHB's effects and its dangerously narrow dose-response, but is absorbed faster and is more potent by volume, making misdosing even easier. As with GHB, the combination with alcohol markedly raises the risk of coma and death.

1,4-Butanediol (BDO) is an industrial solvent and a prodrug of GHB: it is metabolised in the liver to GHB via alcohol and aldehyde dehydrogenase. Its effects, narrow dose-response and dependence risk mirror GHB, but onset is delayed and variable, and its shared metabolism with ethanol produces a dangerous interaction with alcohol.

DMAA (1,3-dimethylamylamine) is a synthetic aliphatic amine stimulant once marketed as a nasal decongestant and later sold widely in pre-workout and weight-loss supplements. It raises blood pressure and heart rate and has been linked in case reports to hypertension, cardiac events, cerebral haemorrhage and stroke, prompting regulators including the FDA to warn against it and remove it from supplements.

Methoxetamine (MXE) is an arylcyclohexylamine dissociative that emerged around 2010 as a 'research chemical' analogue of ketamine, marketed as bladder-friendly though this was never established. It has a longer duration and higher potency than ketamine and was linked to several deaths and hospitalisations before being widely banned.

DMHA (2-aminoisoheptane, octodrine) is a synthetic aliphatic amine stimulant used in pre-workout and fat-burner supplements, often as a successor to DMAA. It is a sympathomimetic that raises energy, focus and blood pressure. Human safety data are limited, but its close similarity to DMAA raises comparable cardiovascular concerns, and regulators including the FDA consider it an unlawful supplement ingredient.

Phenazepam is a potent, long-acting benzodiazepine developed in the Soviet Union in the 1970s and still used medically in Russia and some post-Soviet states. Elsewhere it spread as a research chemical and drug of misuse. It is strongly sedating with a long half-life, and has been implicated in many intoxication and overdose deaths, especially in combination with opioids or alcohol.

Adinazolam is a triazolobenzodiazepine originally investigated in the 1980s as an antidepressant-anxiolytic but never marketed. It is now encountered as a grey-market designer benzodiazepine. It has both anxiolytic and sedative activity and is metabolised to the more potent N-desmethyladinazolam.

Rilmazafone is a water-soluble benzodiazepine prodrug developed and marketed in Japan as a hypnotic. It is inactive until metabolised in the gut to an active benzodiazepine. It has genuine Japanese clinical use as a sleep aid, but is treated as a research chemical elsewhere and shares the dependence profile of the class.

LSA (ergine, D-lysergic acid amide) is a naturally occurring ergoline alkaloid found in morning glory and Hawaiian baby woodrose (HBWR) seeds. It is a mild, sedating psychedelic relative of LSD, usually consumed by ingesting ground seeds. Nausea and heavy body load are prominent, and human data remains largely observational.

A substituted cathinone stimulant (3-chloromethcathinone) that replaced 3-MMC in several European markets after scheduling. Short-acting with a strongly compulsive redose pattern and almost no formal pharmacology.

Gidazepam is a benzodiazepine prodrug developed in the former Soviet Union and used medically in some post-Soviet states as an anxiolytic. It is metabolised to the long-acting active compound desalkylgidazepam. On the grey market it is sold as a research chemical; human data come mainly from regional clinical use.

3-MeO-PCP is a potent arylcyclohexylamine dissociative and PCP analogue sold as a research chemical. It is notably stimulating and has a narrow margin of safety, with a well-documented risk of overdose, agitation and stimulant-type psychosis. It has been implicated in multiple hospitalisations and deaths.

Methoxphenidine (MXP, 2-MeO-diphenidine) is a diarylethylamine dissociative that emerged around 2013 as a legal ketamine substitute. It is an NMDA receptor antagonist producing dissociation, stimulation and, at higher doses, anaesthesia and confusion. Human data are limited to case reports and anecdote, and it has been implicated in several deaths.

Diphenidine (DPD) is a diarylethylamine dissociative that appeared as a research chemical around 2013, often alongside methoxphenidine. It is an NMDA receptor antagonist producing dose-dependent dissociation, stimulation and anaesthesia. Human data are limited to case reports and anecdote, and it has featured in several intoxication and death investigations.

3-Hydroxyphenazepam is a designer benzodiazepine and an active metabolite of phenazepam. It is sold as a research chemical and produces the sedative, anxiolytic and amnestic effects typical of the class, with a long duration. Human data is essentially limited to its role as a phenazepam metabolite and to user reports.

4-MeO-PCP is an arylcyclohexylamine dissociative and PCP analogue sold as a research chemical. It is markedly less potent than PCP or 3-MeO-PCP and is described as milder and more manageable, though human data are minimal and confined to anecdote.

Diclazepam (chlorodiazepam) is a designer benzodiazepine and a chlorine analogue of diazepam. It is long-acting, high-potency, and sold as a research chemical with no clinical development. Effects mirror classic benzodiazepines: anxiolysis, sedation, muscle relaxation and amnesia, with a correspondingly high potential for dependence and dangerous additive respiratory depression when combined with opioids or alcohol.

Ephenidine (NEDPA) is a diarylethylamine dissociative and NMDA receptor antagonist that appeared as a research chemical in the mid-2010s. It produces dose-dependent dissociation, stimulation and anaesthesia, with human information limited to anecdote and a small number of pharmacology studies. It is typically taken orally.

Naphyrone (naphthylpyrovalerone, O-2482) is a pyrrolidine synthetic cathinone in the pyrovalerone family, distinguished by a naphthalene ring in place of the phenyl group. It gained notoriety after the UK mephedrone ban as 'NRG-1'. It is a potent triple monoamine reuptake inhibitor with strong compulsive potential; human data remains limited.

Tenocyclidine (TCP) is a thiophene analogue of PCP in which the phenyl ring is replaced by a thienyl group. It is a potent NMDA receptor antagonist studied largely in preclinical pharmacology as a research tool, with essentially no controlled human data. It shares PCP's dissociative and psychotomimetic profile and is reported to be more potent.

1B-LSD is a semisynthetic lysergamide, the 1-butanoyl derivative of LSD, sold as a research chemical on blotter. It is generally regarded as a prodrug or slightly less potent analogue of LSD, producing comparable psychedelic effects. Human data is limited to user reports; no clinical studies exist.

1D-LSD is a semisynthetic lysergamide bearing a 1-cyclopropanecarbonyl-related acyl group on the LSD nitrogen, distributed as a research chemical largely in Germany. It behaves as a prodrug or near-equivalent of LSD with comparable psychedelic effects. Human data is limited to user reports.

Flubromazepam is a designer benzodiazepine with an exceptionally long half-life, first synthesised in 1960 but never developed clinically. A single dose can produce measurable effects and impairment for days. Sold as a research chemical, its very slow elimination makes accumulation, prolonged sedation, dependence and additive respiratory depression with opioids or alcohol its defining hazards.

Pyrazolam is a designer triazolobenzodiazepine structurally related to alprazolam and bromazepam. It is primarily anxiolytic with comparatively little sedation or euphoria, and is notable for not being metabolised into other active benzodiazepines. Sold as a research chemical, it still carries benzodiazepine dependence risk and dangerous additive respiratory depression with opioids or alcohol.

4-CMA (para-chloromethamphetamine, PCMA) is a ring-chlorinated methamphetamine analogue and potent serotonin-releasing agent. Unlike the beta-keto cathinones, it is a non-ketone amphetamine, but it circulated in the same research-chemical niche. It is notable for marked serotonergic neurotoxicity in animals and a high serotonin-syndrome risk, with essentially no legitimate human use.

Fonazepam, also known as 3-fluorophenazepam, is a designer benzodiazepine structurally derived from phenazepam. It is sold as a research chemical and reported to be long-acting and potent, producing sedation, anxiolysis and amnesia. No clinical human data exists; information is limited to analytical characterisation and user reports.

LSM-775 is a lysergamide in which the diethylamide of LSD is replaced by a morpholide group. It is a lesser-known psychedelic reported to be shorter-acting and somewhat less potent than LSD, with a more sedated character. Human information is very limited and largely historical or anecdotal.

Meclonazepam is a designer benzodiazepine originally investigated in the 1970s as an antiparasitic (schistosomicidal) agent. It is a methylated analogue of clonazepam with strong sedative, anxiolytic and muscle-relaxant activity. Sold as a research chemical, it carries the benzodiazepine class risks of dependence and additive respiratory depression with opioids or alcohol.

Norfludiazepam (norflurazepam) is a long-acting designer benzodiazepine and an active metabolite of several licensed benzodiazepines including flurazepam and fludiazepam. It is sold as a research chemical and produces prolonged sedation and anxiolysis.

Eticyclidine (PCE, N-ethyl-1-phenylcyclohexylamine) is an arylcyclohexylamine dissociative closely related to PCP, differing by an N-ethyl rather than piperidine group. It is an NMDA receptor antagonist with a dissociative, psychotomimetic profile and only anecdotal human data. It appeared as a grey-market research chemical and is controlled in many jurisdictions.

alpha-PBP (alpha-pyrrolidinobutiophenone) is a pyrrolidine synthetic cathinone in the pyrovalerone family, a shorter-chain homologue of alpha-PVP. Sold as a research chemical, it is a potent dopamine reuptake inhibitor with strong compulsive potential. Human data is minimal and all information is anecdotal.

2-Oxo-PCE (eticyclidone, O-PCE) is an arylcyclohexylamine dissociative closely related to eticyclidine, bearing a ketone group analogous to the ketamine series. It is an NMDA receptor antagonist that appeared as a research chemical in the 2010s. Human data are anecdotal, describing a potent, relatively short dissociative.

4-EMC (4-ethylmethcathinone) is a synthetic cathinone stimulant closely related to mephedrone, differing by an ethyl rather than methyl substituent on the aromatic ring. It surfaced on the research-chemical market as a legal-grey alternative to banned cathinones. Human data is essentially absent; reported effects are entirely anecdotal and describe a milder, more empathogenic and less euphoric profile than mephedrone.

4F-PVP (4'-fluoro-alpha-pyrrolidinopentiophenone) is a fluorinated analogue of alpha-PVP, a pyrrolidine synthetic cathinone sold as a research chemical. It is a potent dopamine reuptake inhibitor with strong compulsive potential. Human data is essentially absent and all information is anecdotal.

Difludiazepam is a potent designer benzodiazepine bearing two fluorine substituents, sold as a research chemical. It produces the sedative, anxiolytic and amnestic effects of the class and is reported to be strong by weight. It has no clinical human characterisation; information is limited to analytical work and user reports.

Fluclotizolam is a thienotriazolodiazepine designer benzodiazepine, closely related to clotizolam and etizolam. It is sold as a research chemical and reported to be extremely potent by weight, active in the low microgram-to-milligram range. There is no clinical human data; information comes from analytical work and user reports.

MDPPP (3',4'-methylenedioxy-alpha-pyrrolidinopropiophenone) is a pyrrolidine synthetic cathinone combining a methylenedioxy ring with a pyrrolidine core. Sold as a research chemical since the 2000s, it is a dopamine reuptake inhibitor. Human data is minimal and all effect information is anecdotal.

MPBP (4'-methyl-alpha-pyrrolidinobutiophenone) is a pyrrolidine synthetic cathinone stimulant, structurally related to the pyrovalerone/PVP family. Sold as a research chemical, it acts as a potent dopamine reuptake inhibitor. Human data is minimal; anecdotal reports describe strong, compulsive stimulation typical of the pyrrolidinophenone class.

MPHP (4'-methyl-alpha-pyrrolidinohexiophenone) is a synthetic cathinone stimulant of the pyrrolidinophenone family, a longer-chain, ring-methylated relative of pyrovalerone and alpha-PVP. It circulated as a research chemical with no approved use. Human data is essentially absent; reported effects are anecdotal and describe a potent, long-lasting stimulant with heavy redose pressure.

Metizolam (desmethyletizolam) is a thienotriazolodiazepine designer benzodiazepine and a metabolite/analogue of etizolam. It has essentially no clinical study in humans and is sold only as a research chemical. It produces sedation, anxiolysis and amnesia typical of the class.

N-Ethylnorpentylone (ephylone, N-ethylpentylone) is a synthetic cathinone stimulant of the methylenedioxy-substituted series, the N-ethyl homologue of pentylone. It spread widely as an adulterant sold as 'MDMA' or in mislabelled products and has been implicated in mass-overdose events. Human pharmacology is largely uncharacterised; reported effects are anecdotal and describe a long, stimulating, entactogen-like profile with severe redose pressure.

2-CMC (2-chloromethcathinone, clophedrone) is a synthetic cathinone stimulant, the ortho-chloro isomer of the halogenated methcathinone series that includes 4-CMC. It circulated widely as a research chemical after mephedrone bans. Human pharmacology is uncharacterised; reported effects are anecdotal and describe a stimulating, functional profile with a strong redose pull.

3,4-DMMC (3,4-dimethylmethcathinone) is a synthetic cathinone stimulant, a dimethyl ring-substituted analogue of methcathinone closely related to mephedrone. It appeared on the research-chemical market as a legal-grey alternative to banned cathinones. Human data is essentially absent; reported effects are anecdotal and describe a stimulating, mildly euphoric profile with a strong redose pull.

3-Cl-PCP (3-chlorophencyclidine) is a chlorinated analogue of PCP that appeared on the research-chemical market in the 2010s. It is an NMDA receptor antagonist reported to be potent and long-acting, with essentially no formal human data. User reports and its structural relationship to PCP point to comparatively high toxicity and agitation risk.

3-EMC (3-ethylmethcathinone) is the meta-substituted isomer of 4-EMC, a synthetic cathinone sold as a research chemical. Like other meta cathinone isomers it is reported to be more stimulating and less entactogenic than its para counterpart. No human pharmacology has been formally characterised, and all effect and dose information is anecdotal.

4-MPD (4-methyl-alpha-pyrrolidinohexanophenone-adjacent; commonly 4-methyl-pentedrone) is a synthetic cathinone stimulant sold as a research chemical. It combines a 4-methyl ring substituent with a pentedrone-like backbone. Human data is absent; anecdotal reports describe a functional, moderately euphoric stimulant with pronounced redosing.

CE-LAD is a novel lysergamide research chemical, a substituted LAD-series analogue of LSD sold on blotter. It is very new and poorly characterised, reported to produce LSD-like psychedelic effects. Essentially all information comes from a small number of user reports.

Deschloroetizolam is a thienotriazolodiazepine designer benzodiazepine, the dechlorinated analogue of etizolam. It is markedly less potent than etizolam but shares the same sedative, anxiolytic and amnestic profile. There is no formal human clinical data.

Fluorexetamine (FXE) is an arylcyclohexylamine dissociative in the methoxetamine/ketamine family that emerged as a research chemical around 2020. It is an NMDA receptor antagonist producing dose-dependent dissociation and anaesthesia, with a longer duration than ketamine. Human data are anecdotal, and bladder toxicity is a plausible class-shared concern.

Fluorolintane (2-F-DPD) is a fluorinated diarylethylamine dissociative related to diphenidine, appearing as a research chemical in the late 2010s. It is presumed to act as an NMDA receptor antagonist producing dose-dependent dissociation and anaesthesia. There is essentially no formal human data, and its profile is inferred from diphenidine and anecdote.

Hydroxetamine (HXE) is an arylcyclohexylamine dissociative in the ketamine/methoxetamine family that appeared as a research chemical in the late 2010s. It is an NMDA receptor antagonist producing dose-dependent dissociation and anaesthesia. Human information is anecdotal, and bladder toxicity is a plausible concern shared with related ketamine-type dissociatives.

MOPVP (4'-methoxy-alpha-pyrrolidinopentiophenone) is a pyrrolidine synthetic cathinone in the alpha-PVP family, bearing a methoxy substituent on the aromatic ring. Sold as a research chemical, it acts as a potent dopamine reuptake inhibitor. There is essentially no human data; all information is anecdotal.

Nifoxipam (3-hydroxyflunitrazepam) is a designer benzodiazepine and an active metabolite of flunitrazepam. It has strong hypnotic and anxiolytic activity and is sold as a research chemical with essentially no human study data. It carries the standard benzodiazepine hazards of dependence and additive respiratory depression with opioids or alcohol.

Zapizolam is a triazolobenzodiazepine designer drug related to alprazolam, sold as a research chemical. It produces sedation, anxiolysis and amnesia and is reported to be potent by weight. It has no clinical human characterisation; information is limited to analytical detection and user reports.

bk-2C-B (beta-keto 2C-B, code DL-4662) is the cathinone-class beta-keto analogue of the phenethylamine psychedelic 2C-B. Structurally a cathinone by virtue of its beta-keto group, it is sold as a research chemical and reported to combine mild stimulation with faint psychedelic character. Human data is absent; all information is anecdotal.

4-MePPP (4'-methyl-alpha-pyrrolidinopropiophenone) is a synthetic cathinone stimulant of the pyrrolidinophenone family, a short-chain ring-methylated relative of alpha-PPP and MDPPP. It circulated as an early research chemical alongside the first-generation pyrrolidinophenones. Human pharmacology is uncharacterised; reported effects are anecdotal and describe a shorter, milder stimulant than the longer-chain pyrros.

Brephedrone (4-BMC, 4-bromomethcathinone) is a synthetic cathinone stimulant, the para-bromo halogenated analogue of methcathinone in the same series as flephedrone and clephedrone. It circulated as a research chemical with no approved use. Human pharmacology is uncharacterised; reported effects are anecdotal and describe a moderate, somewhat harsh stimulant.

Cloniprazepam is a designer benzodiazepine, the N-cyclopropylmethyl analogue of clonazepam. It is a potent, long-acting sedative and anxiolytic with no clinical study in humans, sold only as a research chemical.

PV-8 (alpha-pyrrolidinoheptiophenone) is a synthetic cathinone stimulant of the pyrrolidinophenone family, a longer seven-carbon chain homologue of alpha-PVP. It appeared on the research-chemical market as a successor to banned pyrrolidinophenones. Human pharmacology is uncharacterised; reported effects are anecdotal and describe a potent, long-lasting stimulant with heavy redose pressure.

TH-PVP (3',4'-tetramethylene-alpha-pyrrolidinovalerophenone; also read as a tetrahydronaphthalene-fused PVP) is a fused-ring pyrrolidine synthetic cathinone related to alpha-PVP and naphyrone. Sold as a research chemical, it is presumed to be a potent dopamine reuptake inhibitor. Human data is essentially absent and all information is anecdotal.

alpha-PBT (alpha-pyrrolidinobutiothiophenone) is a thiophene-based pyrrolidine synthetic cathinone, replacing the phenyl ring of alpha-PBP with a thiophene ring. Sold as a research chemical, it is presumed to act as a dopamine reuptake inhibitor. Human data is essentially absent and all information is anecdotal.

4-MTMC (4-methylthiomethcathinone) is a synthetic cathinone stimulant bearing a methylthio group at the para position of the aromatic ring. It is a niche research-chemical analogue of methcathinone with essentially no published human pharmacology. All reported effects are anecdotal and describe a mephedrone-like stimulant character.

Flunitrazolam is a triazolo analogue of flunitrazepam and one of the most potent designer benzodiazepines known, active in the microgram range. It has no clinical study in humans and carries a high risk of overdose because minute quantities are strongly sedating.

Isopentedrone is a synthetic cathinone stimulant, a branched-chain isomer of pentedrone (a beta-keto amphetamine with a methylamino group). It is a niche research chemical with essentially no published human pharmacology. Reported effects are anecdotal and describe a pentedrone-like stimulant with a strong redose pull.

PV-9 (alpha-pyrrolidinooctiophenone) is a synthetic cathinone stimulant of the pyrrolidinophenone family, an eight-carbon chain homologue extending the PV-8/alpha-PVP series. It is a niche research chemical with essentially no published human pharmacology. Reported effects are anecdotal and describe a potent, long-lasting stimulant with heavy redose pressure.

alpha-D2PV (alpha-di(2-thienyl)pyrrolidinopentane, or a dihydro/dithienyl pyrrolidinovalerophenone analogue) is a niche synthetic cathinone-type stimulant of the pyrrolidinophenone family, structurally related to alpha-PVP with a modified aromatic system. It has essentially no published human pharmacology; reported effects are anecdotal and describe a potent, focused stimulant with heavy redose pressure.